Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of
about
Interventions for mycosis fungoidesEORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphomaPruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative ReviewSystemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.Bendamustine salvage therapy for T cell neoplasms.Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indicationsMycosis fungoides: case report and literature review.A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classificationIdentification of p38β as a therapeutic target for the treatment of Sézary syndrome.Guidelines on the use of extracorporeal photopheresisEvaluation of cardiovascular disease risk factors in patients with mycosis fungoides.c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.Treating cutaneous T-cell lymphoma with highly irregular surfaces with photon irradiation using rice as tissue compensatorPhase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humansRapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapyNivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyNovel therapeutic agents for cutaneous T-Cell lymphoma.Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary teamFlow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides.Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaResults of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.Emerging treatment options for early mycosis fungoides.Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiologyAllogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.FDG-PET imaging in hematological malignanciesManagement Strategies for Mycosis Fungoides in India.Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group.
P2860
Q24200749-17B3BF96-3B61-47D3-BBDB-6406B939DB36Q27000343-01E817E9-F7C3-4E2F-964A-CD5D3BFAD5C2Q28075343-AAC8E964-2AF7-4BA4-B443-06132E983418Q30239965-979D5CCC-39C7-49E6-821C-18F629B3F59FQ30252152-AD912922-CFFD-45B2-87E9-3ACC229CE780Q30276550-02C16297-666E-4685-8B60-54D380A0A4F6Q30650570-74DE44F8-537F-475F-83BF-74D9AFE6ADC4Q33407099-ACEADFA6-19EE-48FB-93DC-18A0B6247B1BQ33429707-5870A3D8-C314-4602-80E7-F0C0D5767A84Q33746059-486D2A0D-EC20-4FF2-8703-4FD1DDD865C0Q34156362-3DE42F3F-C3AB-4285-81E7-90B230E16A12Q34353111-B2710832-12E9-4A77-9313-45B80C5B0918Q34362184-676F7C95-9D91-4A3A-A9BD-C9BD2A91B540Q34663865-1BA49C7E-F501-4E65-9381-6EC44D26256EQ34899213-517517B1-02F4-462F-960C-E7C45C562D47Q34918643-3D801B17-F27E-4931-85C7-CC1ACD2A34A5Q35070294-3DF40A76-2221-46A7-9589-3672A5F8D3BCQ35071772-C1FC4ACD-EC9B-42A1-883A-11BDB73B2F9FQ35114800-C4F181F4-3779-4921-9EA1-C0D90A875E50Q35222112-F6FB4E1F-4D09-46E3-9797-3E33BDE4D5F3Q35584244-60AF0698-2071-4AC0-974D-91C0D649A5BFQ35669197-23C14935-B923-40EE-886F-36116A2FAE6CQ35740445-7A4257F2-ACCE-498A-AF8A-8903D8A74E6AQ35825986-47A7E4FF-127C-4991-80CD-9414454EB0E0Q36043066-19CC693A-81F7-49FF-ACF2-690BC876CF42Q36161365-4DEE90B5-22BE-4FCB-BC24-33C0C86F9268Q36383242-294125E3-1328-416F-B614-297B0458A7ACQ36415896-F39ED821-D785-4754-AA9D-858038949F97Q36519044-7371DFEC-F0B3-43A6-A926-75F1FA20F870Q36534677-654C0D87-D2A9-4122-B96B-9730BC40C5E9Q36635567-C6A8DC51-158A-4D22-A8E3-2C4ADB46FB92Q36870654-CDEB09F6-F39A-4A8F-82DD-22CF5B0BA41DQ37323004-D67B5E25-5C03-410D-9254-D9F3F1A52A94Q37384289-AA13209B-03AB-440D-B39A-DA168922117CQ37509450-9B2AE97C-8429-439D-A93F-436FF203869DQ37618920-693B3F11-C856-4EB2-B126-22F41F27991AQ37632114-422389D6-5DEF-40F8-8C64-B223DBA53980Q37717711-243E60B1-2323-48B1-9732-0BED70296480Q37998019-4E00DC11-02F4-41C1-B925-1AF93859392EQ38035410-56A0728A-9CDC-48FE-9124-69C56E72DB11
P2860
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Clinical end points and respon ...... taneous Lymphoma Task Force of
@ast
Clinical end points and respon ...... taneous Lymphoma Task Force of
@en
type
label
Clinical end points and respon ...... taneous Lymphoma Task Force of
@ast
Clinical end points and respon ...... taneous Lymphoma Task Force of
@en
prefLabel
Clinical end points and respon ...... taneous Lymphoma Task Force of
@ast
Clinical end points and respon ...... taneous Lymphoma Task Force of
@en
P2093
P2860
P356
P1476
Clinical end points and respon ...... search and Treatment of Cancer
@en
P2093
Annamari Ranki
Brigette Dreno
Cutaneous Lymphoma Task Force ...... search and Treatment of Cancer
Elise A Olsen
Eric C Vonderheid
Gary S Wood
Günter Burg
H Miles Prince
International Society for Cutaneous Lymphomas
Joan Guitart
P2860
P304
P356
10.1200/JCO.2010.32.0630
P407
P577
2011-05-16T00:00:00Z